Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
52 hedge funds and large institutions have $18.1M invested in Harpoon Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 14 closing their positions.
80% more call options, than puts
Call options by funds: $18K | Put options by funds: $10K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less funds holding
Funds holding: 63 → 52 (-11)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
52% less capital invested
Capital invested by funds: $37.6M → $18.1M (-$19.5M)
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
+$1.08M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$333K |
| 3 |
Renaissance Technologies
New York
|
+$306K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$204K |
| 5 |
Millennium Management
New York
|
+$189K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.66M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$630K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$458K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$244K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$242K |
HARP Hedge Fund Activity: Q3 2022 in Review
52 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q3 2022, worth a combined $18.1M — down 52% from $37.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of HARP and 3 opened new positions — a net loss of 11 holders — while 18 trimmed existing stakes and 10 added.
The largest buyer was Piper Sandler & Co, opening a new position worth an estimated $1.08M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.66M sold.
- 52 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q3 2022, down from 63 in Q2 2022.
- Funds reported $18.1M of Harpoon Therapeutics, Inc. Common Stock stock for Q3 2022, down 52% quarter-over-quarter.
- 3 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -11 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q3 2022 was Piper Sandler & Co, an estimated $1.08M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q3 2022 was Point72 Asset Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q3 2022.